NCT06512792 Mobile App-Based Remote Management Model for IBD Patient
| NCT ID | NCT06512792 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Changhai Hospital |
| Condition | Inflammatory Bowel Diseases |
| Study Type | INTERVENTIONAL |
| Enrollment | 500 participants |
| Start Date | 2024-01-01 |
| Primary Completion | 2025-07-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 500 participants in total. It began in 2024-01-01 with a primary completion date of 2025-07-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Inflammatory Bowel Disease (IBD) is a chronic inflammatory condition of the intestines, with its incidence showing a significant year-on-year increase in China. Self-management is becoming increasingly important in the treatment and follow-up of IBD. Numerous studies from Europe and North America have demonstrated that telemedicine can effectively manage disease activity, monitor symptoms, provide education, and improve prognosis. However, its application in China is limited, and there is a lack of high-quality clinical research. This study aims to explore the following objectives: 1. Investigate the level of disease awareness among Chinese IBD patients and their needs related to telemedicine; 2. Develop and preliminarily establish a telemedicine management system and operational process for IBD patients based on a mobile application platform; 3. Clarify the impact of telemedicine on disease activity, quality of life, and healthcare resource utilization among Chinese IBD patients.
Eligibility Criteria
Inclusion Criteria: 1. Patients will be diagnosed with IBD based on the diagnostic criteria outlined in the "Consensus on Diagnosis and Treatment of Inflammatory Bowel Disease (2018, Beijing)". The diagnosis will be established by combining clinical symptoms, endoscopic examination results, imaging findings, and histological examination results. 2. Participants must be between the ages of 18 and 75 and provide signed informed consent for the project. 3. Within the two years prior to enrollment, medical records must show at least one instance assessed as an inflammatory active phase (Mayo score ≥ 3 or CDAI score ≥ 150). Exclusion Criteria: 1. Participants deemed unable to adhere to the study protocol as determined by the investigators. 2. Individuals with a history of surgical treatment for IBD or those scheduled to undergo surgery. 3. Uncontrolled internal medicine or psychiatric disorders. 4. Pregnant individuals or those planning to become pregnant during the enrollment and follow-up period.
Contact & Investigator
Zhaoshen Li, Professor
STUDY DIRECTOR
Changhai Hospital
Frequently Asked Questions
Who can join the NCT06512792 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Inflammatory Bowel Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06512792 currently recruiting?
Yes, NCT06512792 is actively recruiting participants. Contact the research team at fan18301972695@163.com for enrollment information.
Where is the NCT06512792 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT06512792 clinical trial?
NCT06512792 is sponsored by Changhai Hospital. The principal investigator is Zhaoshen Li, Professor at Changhai Hospital. The trial plans to enroll 500 participants.